Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

Home Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

/ Publications

Share the Post

About the Author

Related Posts

Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)
Read More
Karin Hehenberger, MD, PhD
Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)
New Drug Trial Gives Hope for Treatment-Resistant Epilepsy
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa
Read More
Scott Giacobello, CPA

Comments

Comments are closed.